BioAtla investors back board nominees and pay plan
BioAtla, Inc. held its 2026 annual meeting of stockholders on July 16, 2026, with 906,983 shares of common stock represented in person virtually or by proxy, approximately 55% of the total outstanding shares eligible to be voted.
Rhea-AI Filing Summary
BioAtla, Inc. held its 2026 annual meeting of stockholders on July 16, 2026, with 906,983 shares of common stock represented in person virtually or by proxy, approximately 55% of the total outstanding shares eligible to be voted. Stockholders considered director elections, auditor ratification and executive compensation.
Two Class III directors, Jay M. Short, Ph.D. and Edward Williams, were elected to three-year terms. Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. A non-binding advisory resolution approving the compensation of named executive officers also received stockholder approval.
Positive
- None.
Negative
- None.
8-K Event Classification
Key Figures
Key Terms
broker non-votes financial
non-binding advisory vote financial
independent registered public accounting firm financial
emerging growth company financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What was voted on at BioAtla (BCAB)'s 2026 annual meeting?
Were BioAtla (BCAB) Class III director nominees elected, and with how many votes?
Did BioAtla (BCAB) stockholders ratify Ernst & Young as auditor for 2026?
How did BioAtla (BCAB) stockholders vote on executive compensation in 2026?
Was there a quorum for BioAtla (BCAB)'s 2026 annual stockholder meeting?
AI-generated analysis. How Rhea-AI works. Not financial advice.